LQDA

Companies
NASDAQ
Liquidia Corporation
Health Care
Price Chart
Overview

About LQDA

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Market Cap
$1.1B
Volume
11.4M
Avg. Volume
12.9M
P/E Ratio
-8.102565
Dividend Yield
0.00%
Employees
111.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.76
Moderate Correlation
Volatility
High (0.55)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for LQDA.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, LQDA shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$1.1B
Volume11.4M
P/E Ratio-8.10
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 19, 2025
Related Securities

PortfolioPilot Analysis

Get AI-powered insights on how LQDA fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025